» Articles » PMID: 38584878

Prognostic Factors to Predict Postoperative Survival in Patients with Recurrent Glioblastoma

Overview
Date 2024 Apr 8
PMID 38584878
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There are no generally accepted criteria for selecting patients with recurrent glioblastoma for surgery. This retrospective study in a Danish population-based cohort aimed to identify prognostic factors affecting postoperative survival after repeated surgery for recurrent glioblastoma and to test if the preoperative New Scale for Recurrent Glioblastoma Surgery (NSGS) developed by Park CK et al could assist in the selection of patients for repeat glioblastoma surgery.

Methods: Clinical data from 66 patients with recurrent glioblastoma and repeated surgery were analyzed. Kaplan-Meier plots were produced to illustrate survival in each of the three NSGS prognostic groups, and Cox proportional hazard regression was used to identify prognostic variables. Multivariable analysis was used to identify differences in survival in the three prognostic groups.

Results: Six variables significantly affected postoperative survival: preoperative Karnofsky Performance Status (KPS) < 70 ( = 0.002), decreased KPS after second surgery ( = 0.012), ependymal involvement ( = 0.002), tumor volume ≧ 50 cm ( = 0.021), age ( = 0.033) and Ki-67 ( = 0.005). Retrospective application of the criteria previously published by Park CK et al showed that median postoperative survival for the three prognostic groups was 390 days (0 points), 279 days (1 point), and 80 days (2 points), respectively.

Conclusion: Several prognostic variables to predict postoperative survival in patients with recurrent glioblastoma were identified and should be considered when selecting patient for repeat surgery. The NSGS scoring system was useful as there were significant differences in postoperative survival between its three prognostic groups.

Citing Articles

Can Platelet-to-Lymphocyte Ratio (PLR) and Neutrophil-to-Lymphocyte Ratio (NLR) Help Predict Outcomes of Patients With Recurrent Glioblastoma?.

Zemskova O, Yu N, Leppert J, Loser A, Rades D In Vivo. 2024; 38(5):2341-2348.

PMID: 39187342 PMC: 11363804. DOI: 10.21873/invivo.13700.

References
1.
Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

2.
Ammirati M, Galicich J, Arbit E, Liao Y . Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery. 1987; 21(5):607-14. DOI: 10.1227/00006123-198711000-00001. View

3.
Stark A, Hedderich J, Held-Feindt J, Mehdorn H . Glioblastoma--the consequences of advanced patient age on treatment and survival. Neurosurg Rev. 2006; 30(1):56-61. DOI: 10.1007/s10143-006-0051-7. View

4.
Park C, Kim J, Nam D, Kim C, Chung S, Kim Y . A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma. Neuro Oncol. 2013; 15(8):1096-101. PMC: 3714158. DOI: 10.1093/neuonc/not069. View

5.
Jakobsen J, Hasselbalch B, Stockhausen M, Lassen U, Poulsen H . Irinotecan and bevacizumab in recurrent glioblastoma multiforme. Expert Opin Pharmacother. 2011; 12(5):825-33. DOI: 10.1517/14656566.2011.566558. View